112.69
price up icon1.93%   2.13
 
loading
Precedente Chiudi:
$110.56
Aprire:
$110.74
Volume 24 ore:
8.09M
Relative Volume:
1.28
Capitalizzazione di mercato:
$139.83B
Reddito:
$28.80B
Utile/perdita netta:
$6.31B
Rapporto P/E:
22.42
EPS:
5.0273
Flusso di cassa netto:
$9.37B
1 W Prestazione:
+0.53%
1M Prestazione:
-0.27%
6M Prestazione:
+0.27%
1 anno Prestazione:
+33.88%
Intervallo 1D:
Value
$109.66
$113.59
Intervallo di 1 settimana:
Value
$108.46
$114.86
Portata 52W:
Value
$83.98
$121.83

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
112.69 137.18B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
839.87 734.96B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
188.64 447.90B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
233.91 417.90B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.39 253.54B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
89.19 223.58B 63.43B 16.42B 14.72B 6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-19 Aggiornamento Daiwa Securities Neutral → Outperform
2025-08-08 Aggiornamento Truist Hold → Buy
2025-07-25 Aggiornamento Needham Hold → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
Oct 03, 2025

Gilead Sciences (GILD) Laps the Stock Market: Here's Why - sharewise.com

Oct 03, 2025
pulisher
Oct 03, 2025

RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD) - Insider Monkey

Oct 03, 2025
pulisher
Oct 03, 2025

Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways - Yahoo Finance

Oct 03, 2025
pulisher
Oct 03, 2025

How Gilead Sciences Inc. (Common Stock) (GIS0) stock responds to bond marketMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock recover faster than industry2025 Year in Review & Stock Portfolio Risk Control - newser.com

Oct 02, 2025
pulisher
Oct 02, 2025

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo

Oct 02, 2025
pulisher
Oct 02, 2025

Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock. - Barron's

Oct 02, 2025
pulisher
Oct 01, 2025

Gilead stock faces potential hit if Biktarvy is Trump’s price cut target - Investing.com

Oct 01, 2025
pulisher
Oct 01, 2025

Potential Price Pressures for Gilead (GILD) Shares - GuruFocus

Oct 01, 2025
pulisher
Oct 01, 2025

RBC on Gilead Sciences (GILD): 'Could Biktarvy Be The $137 Pill Trump Wants To Cut To $18' - StreetInsider

Oct 01, 2025
pulisher
Oct 01, 2025

Marginal Zone Lymphoma Market Growth Projections 2024-2034: DelveInsight Analysis | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma - The Globe and Mail

Oct 01, 2025
pulisher
Oct 01, 2025

Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire Inc.

Oct 01, 2025
pulisher
Oct 01, 2025

Using flow based indicators on Gilead Sciences Inc.2025 Sector Review & Short-Term High Return Strategies - newser.com

Oct 01, 2025
pulisher
Sep 30, 2025

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Sep 30, 2025
pulisher
Sep 30, 2025

How to integrate Gilead Sciences Inc. into portfolio analysis toolsEarnings Miss & Weekly High Conviction Trade Ideas - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

What Do Analysts Think About Gilead Sciences (GILD)? - Insider Monkey

Sep 30, 2025
pulisher
Sep 30, 2025

Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech - BioWorld MedTech

Sep 30, 2025
pulisher
Sep 30, 2025

Gilead Sciences Begins On New California Manufacturing Hub - Construction Equipment Guide

Sep 30, 2025
pulisher
Sep 30, 2025

One Wealth Advisors LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Earnings visualization tools for Gilead Sciences Inc.2025 Risk Factors & Expert Approved Trade Ideas - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Capital Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Raleigh Capital Management Inc. Sells 6,315 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

GC Wealth Management RIA LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Avior Wealth Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 30, 2025
pulisher
Sep 30, 2025

Hong Kong's Health Hope Pharma enters into virology deal with Gilead Sciences - BioSpectrum Asia

Sep 30, 2025
pulisher
Sep 29, 2025

Will Gilead Sciences Inc. stock keep outperforming rivals2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Gilead pumps up virology pipeline with drug transporter deal - Fierce Biotech

Sep 29, 2025
pulisher
Sep 29, 2025

What analyst consensus implies for Gilead Sciences Inc. (GIS) stockSell Signal & Smart Allocation Stock Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences - PR Newswire UK

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi, HHP license oral drug delivery compound to Gilead By Investing.com - Investing.com Canada

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi Pharmaceutical Signs Global Licensing Agreement with Gilead Sciences and Health Hope Pharma for Encequidar - Korea IT Times

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi's Oral Delivery Platform Compound Licensed to Gilead - Eastern Progress

Sep 29, 2025
pulisher
Sep 29, 2025

Real time scanner hits for Gilead Sciences Inc. explainedQuarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi's oral delivery platform compound licensed to Gilead - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi Pharm licenses oral drug delivery compound to Gilead Sciences - StreetInsider

Sep 29, 2025
pulisher
Sep 29, 2025

Short interest data insights for Gilead Sciences Inc.2025 Investor Takeaways & Weekly Momentum Picks - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Gilead Sciences, Inc. $GILD Shares Sold by First County Bank CT - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Hanmi sells Encequidar oral absorption tech to Gilead in up to $34.5M dealCHOSUNBIZ - Chosun Biz

Sep 29, 2025
pulisher
Sep 29, 2025

Will Gilead Sciences Inc. stock deliver strong dividend growth2025 Top Decliners & Weekly Return Optimization Plans - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Morgan Stanley Maintains Buy on Gilead Sciences (GILD) - Insider Monkey

Sep 29, 2025
pulisher
Sep 29, 2025

Why Gilead Sciences Inc. (GIS) stock is a must watch tickerMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Gilead Sciences, Inc. (NASDAQ:GILD) Is Favoured by Institutional Owners Who Hold 88% of the Company - 富途牛牛

Sep 28, 2025
pulisher
Sep 28, 2025

Old Port Advisors Buys Shares of 7,321 Gilead Sciences, Inc. $GILD - MarketBeat

Sep 28, 2025
pulisher
Sep 27, 2025

What analysts say about Gilead Sciences Inc GIS stockREITs Market Trends & Free Risk Assessment and Control - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

Kathmere Capital Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 27, 2025
pulisher
Sep 27, 2025

State of Alaska Department of Revenue Sells 6,285 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Sep 27, 2025
pulisher
Sep 27, 2025

Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum - Yahoo Finance

Sep 27, 2025
pulisher
Sep 26, 2025

How Gilead Sciences Inc. (Common Stock) (GIS0) stock moves in volatile trading sessions2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Is Gilead Sciences Inc. (GIS) stock included in top ETFsBuy Signal & Stock Portfolio Risk Management - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating - MSN

Sep 26, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$50.90
price up icon 1.52%
drug_manufacturers_general PFE
$27.37
price up icon 1.07%
$297.89
price up icon 0.16%
drug_manufacturers_general NVO
$59.63
price up icon 1.52%
drug_manufacturers_general MRK
$89.19
price down icon 0.36%
Capitalizzazione:     |  Volume (24 ore):